drugset
drugset / Trial / NCT04102982

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

NCT04102982 ↗

Phase 2 Unknown 200 enrolled Shandong Provincial Hospital
RandomizedParallel-groupOpen-labelOther

Summary

Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.

Timeline

Start
2019-11-01
Primary completion
2021-10-31
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Camrelizumab Monoclonal antibody 200 mg —

Indications

non-small cell lung carcinoma